Canon Kabushiki Kaisha

Daiichi Sankyo Company, Limited

Sankyo Company, Limited

Tdk Corporation

Fujikura Limited

Pieris Pharmaceuticals Gmbh

Nec Corporation

Victor Company of Japan, Limited

Nof Corporation

Canon Denshi Kabushiki Kaisha

Namco Bandai Games, Ltd.

Hope Co. Ltd.

Dictran International Corp.

Tohru Takahashi

Junichiro Kanbe

Tsutomu Toyono

Nagao Hosono

Yasuyuki Tamura

Shuzo Kaneko

Shunji Nakamura

Ryuji Hashimoto

Andrea Allersdorfer

Christine Rothe

Marlon Hinner

Alexander Wiedenmann

Gabriele Matschiner

Rachida Siham Bel Aiba

Bradley Lunde

Nobufusa Serizawa

Ichiro Kawashima

Ryuta Koishi

Katsuyuki Takei

Shinjiro Okada

Yutaka Inaba

Naoto Kawamura

Hatsuo Tajima

Shinji Yamaguchi

Andreas Hohlbaum

Futoshi Nara

Kazufumi Kubota

Mamoru Otoyo

Tomohiro Nishizawa

Sakiko Takahashi

Takahide Aburatani

Chikako Nagasaki

Mitsuhiro Makino

Hiroshi Inoue

Akihiro Mouri

Tadashi Yoshida

Tadashi Sato

Osamu Taniguchi

Masahiko Enari

Tatsuo Takeuchi

Yoshiyuki Osada

Yujiro Ando

Kazuo Isaka

Kensuke Nakamura

Akihiko Tojo

Hiroyuki Kitayama

Hideyuki Kawagishi

Ryo Fujimoto

Yasuo Mitsuhashi

Yoshiro Udagawa

Hirotoshi Kishi

Fumitaka Kan

Eisuke Tsuda

Tatsuo Chigira

Mitsutoshi Kuno

Takako Kimura

Shigeru Yoshida

Akiyasu Sumi

Takeshi Takizawa

Takashi Shinozaki

Kimihisa Ichikawa

Yoshiharu Hiruma

Toshinori Agatsuma

Nobuo Kitajima

Toshiaki Ohtsuka

Michio Shigenobu

Takayoshi Tsutsumi

Tatsuji Matsuoka

Ichiro Watanabe

Jun Ohsumi

Masashi Kiuchi

Kazuhiko Goto

Ingrid Schuster

Hideyuki Haruyama

Naoya Shinozaki

Chigusa Yoshimura

Akira Kurosawa

Seiji Tomari

Hiroko Yoshida

Shiho Kozuma

Junya Ichikawa

Dirk Ponsel

Sandra Miller

Ulrike Schubert

Kenji Matsui

Shiro Nakayama

Izumi Ishikawa

Hiroshi Niinobe

Toshio Niwa

Chikako Suzuki

Kazuo Watanabe

Akio Shiraishi

Shin Yonehara

Robert Mühlbacher

Kathrin-Ladetzki Baehs

Steffen Runz

Mitutaka Tanida

Thoru Nakatsuka

Hiroyuki Miyata

Charles W Ho

The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.

Anti-CD3 antibody and molecules comprising the antibody

The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Proteins specific for calcitonin gene-related peptide

The present invention provides a peptide library comprising a plurality of mutant peptides based on the extracellular binding domain of the TACI protein. The mutant peptides of the library have the capacity to bind to target molecules other than the endogenous TACI ligands. The present invention further provides a peptide library comprising a plurality of mutant peptides each comprising an amino acid sequence of SEQ ID NO: 1 in the Sequence Listing.

Peptide library

The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.

Nucleic acid molecules encoding muteins of human tear lipocalin which bind PCSK9

Human tear lipocalins which bind PCSK9 and methods of use thereof

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

When a piecehas stopped at an empty element, a castlecan be built at the element, and ownership can be set to the element. When another piecehas stopped at the element to which the ownership has been set, a sub-game is executed so that a player who owns the castle(element), another player who uses a piece, and a third player who uses a piecethat is positioned within a given range from the castleparticipate in the sub-game. When the player who owns the castlehas won the sub-game, the player can collect the cost of staying from the player who uses the piece. When the player who uses the piecehas won the sub-game, the player who uses the piececan acquire the ownership of the castle

Game execution control method, storage medium, and electronic instrument

A composite electronic component provided is one with sufficient impact resistance. In this resonator, a piezoelectric elementis supported by receiversin platelike holding portions, and edge partsin the holding portionsare in contact with a capacitive element. This results in keeping the distance constant between the piezoelectric elementand the capacitive element. Furthermore, even if an impact is exerted on the resonator, the platelike holding portionswill absorb the impact. Therefore, an improvement is made in impact resistance of the resonator

Composite electronic component

A composite electronic component provided is one with sufficient impact resistance. In this resonator, a capacitive elementhas a projectionprojecting outside a piezoelectric element, from a portion of the capacitive elementcoinciding with a vibration region. The projectionis provided on each of two sides of the capacitive elementin a direction substantially perpendicular to a longitudinal direction of the capacitive element. This causes the projectionsof the capacitive elementto be buried in a mold resin, whereby the capacitive elementis sufficiently fixed to the mold resineven if the mold resinis provided with a vibration spacecontaining the vibration regionof the piezoelectric element. Therefore, an improvement is made in impact resistance of the resonator

A lead portionis made of a rod-like metal conductor and has a step portionat its end portion. A first side plateand a second side plateare formed by using thinned portions of the end portion of the lead portion. The first and second side platesandface each other with a distance. One end of the first side plateand one end of the second side plateare continued to each other while the other end of the first side plateand the other end of the second side plateform open end edgesandrespectively.

Lead terminal, resonator and train of electronic components

A high-permittivity rubber compound (MX) to be over 10, 15, or 20 in relative permittivity is produced by filling, to 100 weight parts of base material (M), 300 or more, 400 or more, or 500 or more weight parts of barium titanate family material as powder (M) over 2000 in relative permittivity at temperatures from room temperature to 90&#xb0; C. A high-permittivity rubber compound (M, M) crosslinked by peroxide is heat-treated (S, S) to remove decomposition residue of the peroxide, and powder (BT) of barium titanate family material of industrial grade is washed (S) by de-ionized water (Mc) to remove ionic impurities, suppressing degradation of insulating characteristics.

High-permittivity rubber compounds and power cable members

Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas/Fas ligand system.

Anti-Fas antibodies

The present invention provides expression systems for exogenous polypeptides wherein the polypeptide is expressed as a fusion protein together with clover yellow virus Nuclear Inclusion a (NIa), the NIa component serving to autolyze the fusion protein after expression. This system can be used to express a novel polypeptide which we have designated KM31-7 protein and which is capable of reducing dichloroindophenol and reduced glutathione. This polypeptide is useful in the treatment of disorders caused by oxidative stress.

Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide

Growing community of inventors

Tokyo, Japan

Tohru Takahashi